McGowan v. Medpace, Inc.

2015 Ohio 3743
Ohio Court of Appeals·Decided September 16, 2015·No. C-140634, C-140652·Published·Cited by 5 cases

Opinion

IN THE COURT OF APPEALS

FIRST APPELLATE DISTRICT OF OHIO HAMILTON COUNTY, OHIO

MARY MCGOWAN, M.D., : APPEAL NOS. C-140634 C-140652

Plaintiff-Appellee/Cross- : TRIAL NO. A-1108336 Appellant, : O P I N I O N.

vs.

:

MEDPACE, INC., :

Defendant-Appellant/Cross-

Appellee. :

Civil Appeals From: Hamilton County Court of Common Pleas Judgment Appealed From Is: Reversed and Cause Remanded Date of Judgment Entry on Appeal: September 16, 2015

Freking & Betz, LLC, Randolph Freking and Brian P. Gillan, for Plaintiff- Appellee/Cross-Appellant Mary McGowan, M.D.,

Thompson Hine LLP, Deborah S. Brenneman and George B. Musekamp, for Defendant-Appellant/Cross-Appellee Medpace, Inc.,

The Gittes Law Group, Frederick M. Gittes and Jeffrey P. Vardaro, for Amicus Curiae the Ohio Employment Lawyers Association.

Please note: this case has been removed from the accelerated calendar.

FISCHER, Judge.

{¶1} Defendant-appellant/cross-appellee Medpace, Inc., and plaintiff-

appellee/cross-appellant Mary McGowan, M.D., have appealed from the trial court’s order entering final judgment in favor of McGowan on her claim against Medpace for wrongful discharge in violation of public policy. Because McGowan failed to identify a clear public policy in support of her wrongful-discharge claim, we hold that the trial court erred by failing to grant a directed verdict to Medpace.

Background and Procedure

{¶2} Medpace is a research facility that designs and conducts clinical trials to test new pharmaceuticals. In the spring of 2011, Medpace hired McGowan as an at-will employee to take over duties from one of its retiring physicians, Dr. Evan Stein. McGowan was hired as the executive director of both Medpace’s Clinical Pharmacology Unit (“CPU”) and its Metabolic and Atherosclerosis Research Center (“MARC”). The CPU conducted phase one studies to observe participants’ first exposure to a drug. The MARC conducted later-stage studies on various drugs. The sponsor of each drug study in the MARC selected a principal investigator to run the study. McGowan was responsible for recruiting new studies to the MARC, and she was additionally appointed by Stein to replace him as the principal investigator on studies that he had previously recruited. McGowan had additionally agreed to take over control of Stein’s private practice, the Cholesterol Treatment Center (“CTC”). The CTC was not affiliated with Medpace and was solely owned by Stein, although it was located on Medpace’s premises. Most participants in the MARC studies were patients at the CTC, and the two entities shared employees.

{¶3} Shortly after taking over the CTC, McGowan observed several practices in the facility that troubled her. Stein had prescribed patients a larger dose of medication than was medically necessary, and had then directed the patients to split the prescribed pills. McGowan felt that this practice of pill splitting constituted insurance fraud and compromised patient safety because the written prescription provided to the pharmacy did not match the instructions in a patient’s chart. McGowan was further troubled by Stein’s practice of combining into one chart the medical records of CTC patients who were enrolled in a MARC study. In her opinion, personal information necessary to the CTC chart was irrelevant to treatment in the MARC and should not be contained in the MARC files. Last, McGowan was concerned with the MARC’s practice of leaving patient charts open on carts outside of treatment rooms. She felt that these two practices were in violation of the Health Insurance Portability and Accountability Act (“HIPAA”).

{¶4} McGowan contacted a health-care attorney regarding her concerns about Stein’s pill-splitting and prescription-writing practices. After receiving confirmation from this attorney that her concerns were legitimate, McGowan called a staff meeting on July 22, 2011. At this meeting, she instructed the staff that they had to change the way that prescriptions were written and the way that charts were handled. McGowan stated that Stein’s prescription-writing practices had been fraudulent. After learning of this meeting and McGowan’s accusations, Stein removed McGowan from all activity in both the MARC and CTC via an email sent on July 25, 2011.

{¶5} On July 27, 2011, McGowan met with August Troendle, Medpace’s president and CEO, and Tiffany Khodadad, Medpace’s executive director of human

resources. During this meeting, McGowan raised her concerns about Stein’s prescription-writing practices and the HIPAA violations that she felt she had observed. Troendle told McGowan that it was inappropriate for her to have accused Stein of fraud in front of the staff. He stated that her concerns would be investigated, and he encouraged her to investigate them as well. According to Troendle, McGowan was adamant that Stein had committed fraud and that she had the right to air her concerns to whomever she wished. Troendle clarified to McGowan that she was still the executive director of the MARC, but that he could not control whether Stein retained control of the CTC or the studies at MARC that he had previously recruited. Neither McGowan’s title nor salary changed after Stein took back control of the CTC and his MARC studies.

{¶6} On July 28, 2011, McGowan sent an email to Khodadad, Troendle, and Kay Nolan, Medpace’s general counsel. In the email, McGowan stated that she felt she was being retaliated against for expressing her concerns about improper practices at the CTC. She stated that Troendle had informed her that she would not be restored to director of either the CTC or MARC until she apologized to Stein, and that Troendle had referred to Stein as an “asshole” and an “egomaniac.” Troendle responded to this email, denying that he had referred to Stein in such a manner and clarifying that McGowan remained head of the CPU, but that he had no authority to remove Stein as the principal investigator on Steins’ MARC studies.

{¶7} Following this meeting and email exchange, McGowan continued her duties as director of the CPU. But she felt that she could be fired from Medpace at any point, and she retained an attorney. On August 17, 2011, McGowan attended a standard Medpace staff meeting. At Troendle’s request, she stayed after the meeting

to speak with him. Troendle acknowledged that McGowan had hired an attorney to negotiate her departure from Medpace, but expressed his desire for her to continue her employment. McGowan told Troendle that she was disappointed that he had lied about calling Stein an asshole. Troendle again told McGowan that it had been inappropriate to accuse Stein of fraud in front of the staff. McGowan stated that Troendle could not stop her from speaking the truth and she accused Troendle of trying to intimidate her.

{¶8} After that meeting, Troendle determined that he had to terminate McGowan’s employment with Medpace. On August 18, 2011, two representatives from Medpace’s department of human resources informed McGowan that she had been fired.

{¶9} On October 19, 2011, McGowan sued Medpace for wrongful discharge in violation of public policy, sex discrimination, intentional infliction of emotional distress, and promissory estoppel. The case proceeded to a jury trial. At the close of McGowan’s case, Medpace moved for a directed verdict. As relevant to this appeal, Medpace argued in its motion that McGowan’s claim for wrongful discharge in violation of public policy failed as a matter of law, because she had failed to establish the first two elements of that claim. The trial court denied Medpace’s request, both when initially made and when it was renewed at the close of all evidence. The jury found in favor of Medpace on McGowan’s claims for sex discrimination, intentional infliction of emotional distress, and promissory estoppel. But it found in favor of McGowan on her claim for wrongful discharge in violation of public policy. It awarded her $300,000 in compensatory damages, $500,000 in punitive damages, and attorney fees.

Free access — add to your briefcase to read the full text and ask questions with AI

McGowan v. Medpace, Inc., 2015 Ohio 3743 (Ohio Ct. App. 2015).

2015 Ohio 3743 (McGowan v. Medpace, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

McGowan v. Medpace, Inc.
2017 Ohio 4396 (Ohio Supreme Court, 2017)
McGowan v. Medpace, Inc. (Slip Opinion)
2017 Ohio 1340 (Ohio Supreme Court, 2017)